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Abstract 
Ethnopharmacological relevance: The roots of Nauclea latifolia Smith (Rubiaceae) popularly 
known as “koumkouma” is used in traditional Cameroonian medicine as neuropathic pain 
remedy and for the treatment of headache, inflammatory pain and convulsion. 
Aim of the study: This study was conducted to evaluate the antinociceptive effects of the 
alkaloid fraction isolated from Nauclea latifolia in neuropathic pain induced by chronic 
constriction injury (CCI) of the sciatic nerve in rat. 
Materials and methods: Bioactive-guided fractionation of the root extracts of Nauclea latifolia 
using the Von Frey in a rat model of neuropathic pain (Benett model), afforded a potent anti-
hyperalgesic fraction IV. Further fractionation of this fraction was performed by high-
performance liquid chromatography (HPLC), yielded eight sub-fractions (F1–F8) which were 
tested for antinociceptive effects. The alkaloid fraction (F3) collected by HPLC, exhibited 
potent antinociceptive effects, and the anti-allodynic and anti-hyperalgesic effects of this 
fraction (8, 16, 40 and 80 mg/kg) were determined using the von Frey and acetone tests 
respectively in a rat model of neuropathic pain. Rota-rod performance and catalepsy tests 
were used for the assessment of motor coordination.  
Results: The alkaloid fraction (80 mg/kg) administered intraperitoneally induced a completely 
decreased hyperalgesia 90 min post-dosing. In the acetone test, the Nauclea latifolia fraction 
at 80 mg/kg showed its maximal anti-allodynic effects 120 min post-injection. The areas 
under the curve (AUC) of the anti-allodynic or anti-hyperalgesic effects produced by the 
alkaloid fraction at 80 mg/kg were significantly (p<0.001) greater than the AUC of effects 
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produced by vehicle in CCI rats. The alkaloid fraction did not exhibit any significant effects 
on the spontaneous locomotor activity of the mice in rota-rod performance and no sign of 
catalepsy was observed.  
Conclusion: The analysis of the effects, expressed as the time course of AUC, supports the 
traditional use of Nauclea latifolia in neuropathic pain therapy. The pharmacological and 
chemical studies are continuing in order to characterize the mechanism(s) responsible for this 
anti-hyperalgesic and anti-allodynic action and also to identify the active substances present 
in the roots extracts of Nauclea latifolia. 
 
Keywords: Nauclea latifolia, neuropthic pain, anti-hyperalgesic, anti-allodynic, traditional 
medicine. 
 
Abbreviations 
ANOVA, analysis of variance; ATCC, American Type Culture collection; AUC, areas 
under the curve; CCI, chronic constriction injury; CHO, chinese hamster ovary; EC50, the 
50% effective concentration; F1, fractions; HPLC, high-performance liquid chromatography; 
LD50, median lethal dose; L-NAME,  Nω-L-nitro-arginine methyl ester; MTT; 3-(4, 5 
dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide; NIH, National Institutes of Health. 
 
1. Introduction 
The pathophysiological mechanisms underlying neuropathic pain have been reviewed 
extensively in recent years, and the results reflect both peripheral and central sensitization 
mechanisms (Moalem and Tracey, 2006). The International Association for the Study of Pain 
defines neuropathic pain as pain initiated or caused by a primary lesion or dysfunction in the 
nervous system (Merskey, 1991). Clinically, the presence of neuropathic pain is often 
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characterized by stimulus-independent persistent pain or abnormal sensory perception of pain, 
such as allodynia (a painful response to a normally innocuous stimulus) and hyperalgesia 
(exaggerated pain sensations as a result of exposure to a mildly noxious stimulus) (Ueda and 
Rashid, 2003). Neuropathic pain is pain that arises from damage to the part of the nervous 
system that carries sensory information to the brain. It is difficult to treat because of its 
severity, duration and resistance to simple painkillers. 
Examples of central neuropathic pain include post-stroke pain, affecting up to 8% of 
post-stroke patients, and neuropathic pain associated with multiple sclerosis in 50% of 
patients and with spinal cord injury in 40% of patients (Werhagen et al., 2007). Peripheral 
neuropathic pain states include painful diabetic neuropathy affecting approximately 25% of 
people with diabetes, sciatica, post-surgical and post-traumatic neuralgias. Post herpetic 
neuralgia is an example of a mixed neuropathic pain, with both peripheral and central 
mechanisms, affecting a significant proportion of patients following shingles (Andersen et al., 
1995; Davies et al., 2006; Hewitt et al., 1997; Jung et al., 2004; Kehlet et al., 2006; Osterberg 
et al., 2005; Siddall et al., 2003). Most patients with neuropathic pain respond poorly to 
traditional analgesics and many require a multidisciplinary approach. With current available 
treatments, only 30-50% of patients with neuropathic pain experience meaningful 
improvement in pain and function, and a long-term commitment from the patient and 
physician are required to ensure compliance and appropriate outcomes (Bennett, 2007).  
In the north of Cameroon, the leaves of Nauclea latifolia Smith (Rubiaceae) is used in 
traditional medicine for the treatment of cerebral malaria, behavioural disturbances in 
mentally-retarded children or central nervous system diseases, such as anxiety, depression and 
epilepsy (Dalziel, 1937; Adjanohoun et al., 1996; Arbonnier, 2000). The roots decoction of 
Nauclea latifolia is effective in cases of fever, headache, migraine, pain, inflammatory 
disorders and neuropathic pain (Biholong, 1986; Adjanohoun et al., 1996; Arbonnier, 2000; 
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Amos et al., 2005). Interested in investigating the pharmacological properties of Nauclea 
latifolia Abbah et al. (2009) and Taïwe et al. (2011) have demonstrated that oral 
administration of Nauclea latifolia extracts cause antipyretic, antinociceptive and anti-
inflammatory effects. Earlier chemical studies of Nauclea latifolia have indicated the 
presence of Naucleamides A–F, a new monoterpene indole alkaloids, strictosamide 
(Shigemori et al., 2002, Ata et al., 2009), flavonoids, saponins, tannins, anthraquinones and 
phenols in the Nauclea latifolia extracts (Ngo Bum et al., 2009; Taïwe et al., 2011).  
In the present study, in order to provide a pharmacological basis to the traditional use 
of Nauclea latifolia as antinociceptive therapy in neuropathic pain and to discover novel 
analgesic drugs from natural resources, we investigated the antiallodynic and anti-
hyperalgesic effects of the alkaloid fraction from Nauclea latifolia roots on CCI of the sciatic 
nerve, a rat model of neuropathic pain, using the Von Frey and acetone tests. 
 
2. Materials and methods 
2.1. Plant material 
The roots of Nauclea latifolia was harvested in March 2009 from the National Park of 
Benoué (North Cameroon) and identified in the National Herbarium, Yaoundé Cameroon by 
comparison to an existing voucher specimen No. 20144/SRF/Cam.  
 
2.2. Solvent-guided fractionation of Nauclea latifolia and bioactivity guided studies  
The dried and powdered roots of Nauclea latifolia (1000 g) were extracted with 
acetone/H2O (7:3; 5 l) at room temperature. The combined extracts were evaporated in vacuo 
to afford a dark residue (381.61 g). The residue was suspended in warm water (1 l) and then 
extracted successively with ethyl acetate (0.5 l × 3) and n-butanol (0.5 l × 3), and 
concentrated to give residue A (133.25 g) and B (371.14 g), respectively. The latter was 
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resolved in warm water (1 l), acidified with HCl (1 N) to pH 4-5, and extracted with CHCl3 
(0.5 l × 3). The aqueous layer was neutralized with NaOH (1 N) to pH 9-10 and extracted 
with CHCl3 (0.5 l × 3) once again and concentrated in vacuo to obtain the crude base (136.12 
g; 36.67%). The crude base (136.12 g) was subjected to a chromatography column with silica 
gel and eluted with CHCl3/CH3OH/ 28% NH4OH (50:1:0.1 → 3:1:0.1) to afford thirteen 
fractions: Fr. I (12.51 g; 9.19%), Fr. II (6.34 g; 4.66%), Fr. III (17.68 g; 12.99%), Fr. IV 
(16.35 g; 12.01%), Fr. V (11.45 g; 8.41%), Fr. VI (92.42 mg; 0.07%), Fr. VII (75.43 mg; 
0.05%), Fr. VIII (41.27 mg; 0.03%), Fr. IX (39.15 mg; 0.03%), Fr. X (4.21 g; 3.09%), Fr. XI 
(1.29 g; 0.95%), Fr. XII (56.94 mg; 0.04%), Fr. XII (513.54 mg; 0.38%). Bioactivity-guided 
studies on the extract and fractions using Von Frey test showed that the fraction IV from the 
roots of Nauclea latifolia significantly attenuated mechano-hyperalgesia of all CCI rats with 
85.26 ± 9.17%, compared to the control group. 
 
2.3. Sample preparation, chromatographic analysis and bioactivity guided studies 
10 mg sample of the fractions IV was dissolved in 10 ml methanol. The solution was 
filtered through membrane filter (pore size 0.45 µm) prior to high-performance liquid 
chromatography analysis. The sample was analysed by means of a HPLC system (AKTATM 
Purifier, Amersham Biosciences). The alkaloid fraction derived from Nauclea latifolia was 
analysed by HPLC using a Vydac C18 column (218TP1010, 25 × 10 cm, 10 µm), and for 
elution of the constituents, a gradient of two solvents denoted A and B was employed. The 
mobile phases were (A) 90% acetonitrile with water and (B) 0.1% trifluoroacetic acid with 
water. The flow rate used was 1.0 ml/min and the injection volume was 10 ml. The retention 
time and UV spectrum of major peaks were analyzed. The eluant was monitored at 215 nm. 
The fractions eluted were combined, and then lyophilized [F1(0.03 mg; 0.30%), F2(0.1 mg; 
10%), F3(0.13 mg; 1.30%); F4(0.07 mg; 0,70%), F5(0.11 mg; 1.10%), F6(0.04 mg; 0.40%), 
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F7(0.08 mg; 0.80%), F8(0.16 mg; 1.60%)] (Figure 1), to afford the products as powders. 
Further activity-guided studies on the sub-fractions (F1–F8) showed that the powders yielded 
by F3 exhibited the most potent antinociceptive effects by causing a dose-dependent inhibition 
of mechanical hyperalgesia in CCI rats using Von Frey test. The collected fraction F3 was 
dissolved in vehicle (saline containing dimethyl sulfoxyde 2%) and screned for further 
activities. 
 
2. 4. Animals 
Male Wistar rats (160-180 g), and male and female Swiss mice (25-30 g) were used. 
All animals were housed under standardized conditions in the animal facility on a 12 hrs 
light/dark cycle with food and water available ad libitum. The investigation conforms to the 
Guide for the Care and Use of Laboratory Animal published by the US National Institutes of 
Health (NIH; publication No. 85-23, revised 1996) and received approval of the local ethical 
committee for animal handling and experimental procedure (Ref n◦ FW-IRB00001954). 
 
2.5. Production of neuropathy and behavioral testing 
2.5.1. Surgery 
The chronic constriction injury of the sciatic nerve model was employed according to 
methods described by Bennett and Xie (Bennett and Xie, 1988). Under thiopental sodium 
anesthesia (Sigma chemical, St Louis, USA, 35 mg/kg; i.p.), the right common sciatic nerve 
was exposed by blunt dissection through the biceps femoris, at the level of mid-thigh. 
Proximal to the sciatic trifurcation, the nerve was freed of adhering tissue, and four ligatures 
with 3-0 silk thread were tied loosely around the nerve with a spacing of about 1 mm, taking 
care not to interrupt the epineural circulation. After surgery, the muscle and skin were closed 
in two layers using absorbable chronic catgut 4-0 for the muscle and 3-0 silk thread for the 
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skin. In sham-operated controls, an identical surgical procedure was performed, except that 
the sciatic nerve was not ligatured. All surgical procedures were performed under normal 
sterile conditions by the same person. After operation, the rats were allowed to recover for 1 
week. 
 
2.5.2. Von Frey test 
 To quantify mechanical sensitivity of the foot, a brisk foot withdrawal in response to 
normally innocuous mechanical stimuli was measured as described previously (Kim and 
Chung 1992). Six rats were used for each treatment (n = 6 per group). The rats were placed in 
acrylic cages on top of a wire mesh grid that allowed their paws access to the Von Frey 
filaments. The rats were adapted to the testing situation, and they were allowed to habituate 
until exploratory behaviour diminished for at least 10 min before stimulation was initiated. 
Bending forces of 1, 6, 10 and 15 g to the mid-plantar skin of each hind paw were then 
applied in increasing order from the weakest to the strongest. Beginning with the lowest force, 
the filament was placed on the skin until it bowed slightly, with each filament presented ten 
times at a rate of about 1/s. The paw-withdrawal threshold was defined as the percent force 
eliciting an active withdrawal on the affected ipsilateral paw. A response was recorded every 
30 min for 180 min post-dosing if the rat withdrew its hind paw from the filament. The effects 
of acute administration of the alkaloid fraction from Nauclea latifolia (8, 16, 40 and 80 
mg/kg; i.p.), morphine (Sigma chemical, St Louis, USA, 5.6 mg/kg; s.c.) or vehicle (10 
ml/kg; saline containing dimethyl sulfoxyde 2%, i.p.) on mechanical sensitivity were tested 
between at day 12 post-surgery.  
 
2.5.3. Acetone test 
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To quantify cold sensitivity of the foot, brisk foot withdrawal in response to acetone 
application was measured as described previously (Choi et al., 1994). Six rats were used for 
each treatment (n = 6 per group). With the animals inside acrylic cages on the elevated grid, a 
drop of acetone was delicately applied to the plantar surface of the hind paw without touching 
the skin using a blunt plastic needle connected to a syringe. A response was recorded if the rat 
withdrew its hind paw in response to acetone application. The time spent with the leg 
withdrawn from the floor during the 60 s following exposure to acetone was recorded. Both 
hind legs were tested in each animal, beginning with the unoperated left leg, and each 
stimulus was applied three times at intervals of approximately 5 min. The duration of lifting 
of the hind paw after acetone stimuli was recorded with a stopwatch every 30 min for 180 min 
post-dosing (Dowdall et al., 2005). The effects of acute administration of the alkaloid fraction 
from Nauclea latifolia (8, 16, 40 and 80 mg/kg; i.p.), morphine (5.6 mg/kg; s.c.) or vehicle 
(10 ml/kg; saline containing dimethyl sulfoxyde 2%, i.p.; adequate controls were performed 
with the corresponding vehicles in CCI and sham rats) on cold sensitivity were tested between 
day 12 and day 14 post-surgery.  
 
2.6. Motor assessment and signs of catalepsy 
The motor coordination test was performed to determine side effects of the Nauclea 
latifolia alkaloid fraction using the rotating rod method (Taïwe et al., 2011). The bar rotated at 
a constant speed of 16 revolutions per min. A preliminary selection of mice was made on the 
day of experiment prior to administration of extract or morphine (t0b), excluding those that 
did not remain on the rota-rod bar for two consecutive periods for 45 sec each. Six mice were 
used for each treatment (n = 6 per group). The integrity of motor coordination was assessed 
on the basis of the number of falls from the rota-rod in 180 sec. Selected animals were tested 
immediately at 0 (t0a), 30, 60, 90, and 120 min after administrations of the alkaloid fraction 
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from Nauclea latifolia (8, 16, 40 and 80 mg/kg, i.p.), morphine (5.6 mg/kg, s.c.), or vehicle 
(10 ml/kg; saline containing dimethyl sulfoxyde 2%, i.p.). 
Catalepsy was evaluated according to the standard bar hanging procedure by placing 
the naive mice with both forelegs over a horizontal bar, elevated 4.5 cm from the floor 
(Sanberg et al., 1988). Catalepsy was considered finished when the forepaw touched the floor 
or when the mouse climbed the bar. Eight mice were used for each treatment (n = 8 per 
group). Measurement was performed 30 and 60 min after administration of the alkaloid 
fraction from Nauclea latifolia (8, 16, 40 and 80 mg/kg; i.p.), morphine (5.6 mg/kg; s.c.) or 
vehicle (10 ml/kg; saline containing dimethyl sulfoxyde 2%, i.p.; adequate controls were 
performed with the corresponding vehicles in CCI and sham rats). The time during which the 
mouse maintained the cataleptic position was recorded for up to 300 sec, with three attempts 
allowed to replace the animal over the glass bar. 
 
2.7. Acute toxicity and cell viability essay 
The acute toxicity test for the alkaloid fraction from Nauclea latifolia was carried out 
to evaluate any possible toxicity. Mice of either sex (5 per sex = 10 per group) were divided 
into control and test groups. The first group served as a normal control treated with vehicle 
(10 ml/kg; saline containing dimethyl sulfoxyde 2%, i.p.). The alkaloid fraction from Nauclea 
latifolia was administered intraperitonealy to different groups at the increasing doses of 160, 
320, 640, 960, 1280, 1600 mg/kg. After injections of the alkaloid fraction from Nauclea 
latifolia, mice were allowed access to food and water ad libitum and all animals were 
observed for general behavioral and body weight changes, hazardous symptoms and mortality 
for a period of 14 days after treatment (Taïwe et al., 2011). The median lethal dose (LD50) 
was estimated according to the method described by Litchfield and Wilcoxon (1949). 
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Confirmatory tests were carried out and the LD50 was calculated from the graph of probit 
mortality against dose of the extract. 
Chinese hamster ovary (CHO) cell line from American Type Culture collection 
(ATCC) were maintained at 37°C in 5% CO2 in F-12K nutrient medium (InVitrogen) 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (InVitrogen) and 10,000 
units/ml streptomycine and penicillin (InVitrogen). Chinese cell ovary cell were seeded into 
96 well micro plates at density of approximately 8 × 108 cells/well. After 2 days of culture, 
the cells were incubated for 24 hours at 37°C with various concentrations of the alkaloid 
fraction from Nauclea latifolia (0, 20, 40, 80, 160, 320, 640, 960, 1280 and 1600 µg/ml). 
Control wells containing cell culture medium alone or with cells, both without Nauclea 
latifolia fraction addition, were included in each experiment. The cells were then incubated 3-
(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT; Sigma, St Louis, MO, 
USA) for 30 min. Conversion of MTT into purple colored MTT formazan by the living cells 
indicated the extent of cell viability. The crystals were dissolved with dimethyl sulfoxide and 
the optical density was measured at 540 nm using microplate reader (Biotek ELx-800, Mandel 
Scientific Inc.) for quantification of cell viability. All assays were run in triplicates. Results 
were plotted as percent of cytotoxicity and concentration-response curves were fitted using 
Graph Pad Prism in order to determine the 50% effective concentration (EC50) (Poillot et al., 
2010). 
 
2.8. Data analyses and statistics 
Data are expressed as mean ± S.E.M. The cumulative anti-nociceptive effect during 
the entire observation period (180 min) was determined as the area under the curve (AUC) of 
the time course. The AUCs for each of the assayed drugs were calculated by the trapezoidal 
method (Rowland and Tozer, 1989). The data were compared using a two-way analysis of 
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variance (ANOVA) followed by Bonferroni’s post-hoc tests. A significant statistical 
difference was determined by value of at least p<0.05. ED50 values and 95% confidence 
intervals (95% CI) were determined at the time of the peak effect for each drug by 
semilogarithmic regression analysis or according to Litchfield and Wilcoxon (1949). 
 
3. Results 
3.1. Effects of the alkaloid fraction from Nauclea latifolia on mechanical hyperalgesia  
Ten days after surgery, CCI rats developed statistically significant increases in 
responses to 1, 6, 10 and 15 g von Frey filament stimulation. CCI rats showed 7.25 ± 1.14% 
and 17.29 ± 3.18% of response frequency to 1 g and 6 g von Frey filament stimuli, 
respectively, compared with the sham-operated group, which did not show any reaction. Thus, 
this effect was a mechano-allodynic response. However, the stimuli of 10 g or 15 g von Frey 
filaments produced mechano-hyperalgesic responses in rats on day ten post-surgery. For 
example, when a 10 g filament stimuli was used in the sham group, 5.12 ± 1.53% was the 
observed response, while in CCI rats the percentage of response was 65.81 ± 2.14%. 
Similarly, the stimuli of 15 g Von Frey filaments produced mechano-hyperalgesic responses 
in rats on day twelve post-surgery. When a 15 g filament stimuli was used in the sham group, 
86.87 ± 2.59% was the observed antihyperalgesia, while in CCI rats the percentage of 
response was 8.54 ± 1.83% [F(6, 38) = 92.51; p>0.06]. 90 min post-injection of 80 mg/kg of 
the alkaloid fraction from Nauclea latifolia, significantly attenuated mechano-hyperalgesia of 
all CCI rats with 76.97 ± 4.21% [F(6, 38) = 92.51; p<0.001], compared to the vehicule group 
(Figure 2A). The attenuation was most marked 60 min after injection for 40 mg/kg, and 180 
min for 80 mg/kg. The maximum value of the AUC obtained in the Von test in sham rats 
(anti-hyperalgesic effects) under these experimental conditions was 288.52 ± 14.29  area units 
(a.u.). At 180 min, the AUC was 198.25 ± 15.17  a.u. in CCI animals administered with 80 
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mg/kg of the alkaloid fraction, indicating that mechano-hyperalgesia had been significantly 
reversed [F(6, 38) = 92.51; p<0.05]. The alkaloids fraction showed potent and dose-dependent 
inhibition of mechanical hyperalgesia with an ED50 value (95% CI) of 35.94 (24.25 - 51.39) 
mg/kg (Figure 2B). 
 
3.2. Effects of alkaloids fraction from Nauclea latifolia on cold allodinia  
The three hour time courses of the anti-allodynic effects of the alkaloid fraction from 
Nauclea latifolia and morphine after a single i.p. administration are shown as the anti-
allodynic effects. Pronounced cold allodynia in response to acetone stimulation of the 
ipsilateral hind paw was observed in the CCI group in the acetone test 12 days after surgery. 
The alkaloid fraction from Nauclea latifolia at the dose of 80 mg/kg induced significant anti-
allodynia effects of all CCI rats with 89.38 ± 3.59% [F(6, 29) = 103.62; p<0.001] using the 
acetone test (Figure 3A). The most pronounced effect was observed 2 hours after 
administration of the alkaloid fraction at the dose of 80 mg/kg. The percentage baseline 
allodynia in CCI rats, injected with vehicle, remained the same throughout the observation 
period, whereas the sham operated group did not present any response to this cold stimulus 
during the entire 3 hrs period of observation. The maximum value of the AUC obtained in the 
acetone test (anti-allodynic effect) under these experimental conditions was 271.40 ± 12.51 
a.u. An AUC of 10.34 ± 2.59 a.u. was observed in the CCI rats which did not show anti-
allodynic effects. The alkaloid fraction showed significant differences at 80 mg/kg (149.57 ± 
18.54 a.u.) [F(6, 31) = 145.71; p<0.001] compared with the CCI control group without 
treatment. The alkaloid fraction showed efficient anti-allodynic effects in the CCI model, with 
an ED50 value (95% CI) of 38.26 (22.31 - 49.67) mg/kg (Figure 3B). 
 
3.3. Effects of the alkaloid fraction from Nauclea latifolia on motor coordination 
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The effects of the alkaloid fraction from Nauclea latifolia on motor coordination were 
evaluated by the number of falls from the rotarod apparatus and compared to animals 
receiving the vehicle. This alkaloid fraction did not affected motor coordination at all doses 
tested [F(5, 72) = 103.52; P>0.07). However, a large effect on motor coordination (19.44 ± 
0.91 falls) [F(5, 72) = 103.52; p<0.001] was observed 30 min post administration with 
morphine at the dose of 5.6 mg/kg, compared with vehicle (Table 1). 
The alkaloid fraction from Nauclea latifolia administered intraperitonealy did not 
induce any cataleptic effect either at low doses or at the higher dose. As can be seen in Figure 
4, s.c. administration of morphine (5.6 mg/kg) induced catalepsy at 30 min [F(5, 32) = 
124.39; p<0.01] and 60 min [F(5, 32) = 124.39; p<0.001] (Figure 4). 
 
3.4. Acute toxicity and cell viability assay 
The results indicated that the acute treatment by intraperitoneal route at doses up to 
1600 mg/kg of the alkaloid fraction from Nauclea latifolia did not produce any sign of 
toxicity or death in mice during 24 hours of observation. After 14 days, treated mice did not 
present any visible toxic effect. Furthermore, no lesions or bleedings were observed in 
internal organs such as lungs, kidneys, liver, heart and stomach. Neither absolute body weight 
nor body weight gain was affected by Nauclea latifolia fraction administration at all doses 
throughout the study. Since no death or damage was observed throughout the experiments, the 
LD50 could not be estimated. 
The ability of the alkaloid fraction from Nauclea latifolia to induce cytotoxicity was 
further investigated by using CHO cells and a standard MTT bioassay (Figure 5). As shown, 
incubation for 24 hrs of these cells lines with the Nauclea latifolia fraction, up to a 
concentration of 160 μg/ml, produces no cell toxicity. The toxicity values observed were not 
significantly different from baseline and lower than 9.7 ± 3.5% [F(8, 32) = 147.25; p>0.07]. 
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However, incubation of CHO cells with a higher concentration (640 µg/ml) of the Nauclea 
latifolia fraction produced greater cell death (30.2 ± 3.8%) [F(8, 32) = 147.25; p<0.001]. The 
viability of CHO cells decreased in a concentration-dependent manner (Figure 5) with 
increasing concentrations of extract (EC50 = 772.35 ± 13.41 µg/kg) after 24h treatment. 
 
4. Discussion 
The present study investigated the anti-allodynic and antihyperalgesic effects of the 
alkaloid fraction from Nauclea latifolia on chronic constriction injury of the sciatic nerve as a 
model of neuropathic pain. This model is based on a unilateral loose ligation of the sciatic 
nerve, which is one of the most frequently used models for the study of neuropathic pain and 
its treatment. Chronic constriction injury in rats simulates the clinical condition of chronic 
nerve compression such as that occurring in nerve entrapment neuropathy or spinal root 
irritation by lumbar disk herniation. This model also shows many of the pathophysiological 
properties of chronic neuropathic pain in human subjects, such as allodynia and hyperalgesia 
(Bennett and Xie, 1988; De Vry et al., 2004). In this study, 12 days after CCI, the rats showed 
a relatively high degree of similarity with other studies published on neuropathic pain in terms 
of the degrees of allodynia and hyperalgesia against cold and mechanical stimuli, 
demonstrated by the increased responsiveness to acetone stimulus and von Frey filaments 
(Bennett and Xie, 1988; De Vry et al., 2004; De la O-Arciniega et al., 2009).  
The antinociceptive effects of the alkaloid fraction from Nauclea latifolia was well 
documented herein, as confirmed by the analysis of the AUC of anti-hyperalgesic effects over 
a time course of 3 hours post-dosing. Also, this alkaloid fraction induced a strong attenuation 
of cold allodynia, and the anti-allodynic effects persisted for 3 hours post-administration. 
Similarly, morphine demonstrated antinociceptive effects on mechanical hyperalgesia and 
cold allodynia at the dose of 5.6 mg/kg. It is the most widely used opioid and the standard 
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against which new agents are compared. This opioid drug has demonstrated antinociceptive 
efficacy in several models of nociception (López-Muñoz et al., 1993), including neuropathic 
pain (De Vry et al., 2004). Morphine mediates its actions by binding and activating receptors 
in the peripheral nervous system, as well as those found in inhibitory pain circuits that 
descend from the midbrain to the spinal cord dorsal horn via presynaptic and, to a lesser 
extent, postsynaptic μ-opioid receptors modulating nociceptive transmission (Nicholson, 
2003). Other studies suggest that Nauclea latifolia extracts remarkably decreased both the 
acute and delayed phases of formaline-induced pain in animals and also caused a significant 
reduction in both yeast-induced pyrexia and egg albumin-induced oedema in rats (Abbah et 
al., 2010; Taïwe et al., 2011). The antinociceptive effects exhibited by Nauclea latifolia 
extract in the formalin test was reversed by the systemic administration of naloxone (a non-
selective opioid receptor antagonist), Nω-L-nitro-arginine methyl ester (L-NAME, a NO 
synthase inhibitor) or glibenclamide (an ATP-sensitive K+ channel inhibitor) (Taïwe et al., 
2011). In the course of pharmacological studies, anticonvulsant, anxiolytic and sedative 
properties of Nauclea latifolia roots decoction (Ngo Bum et al., 2009; Taïwe et al., 2010) 
have already been reported from our laboratory. Neuropathic pain and epilepsy share neuronal 
hyperexcitability as a common underlying mechanism. There are established antiepileptic 
drugs that target the generation of neuronal hyperexcitability, and some of these have been 
proven to be effective in the treatment of various forms of neuropathic pain (Sindrup and 
Jensen, 2000). 
The results obtained in our study suggest that inhibition of neuropathic pain by 
Nauclea latifolia is not related to the reduction of spontaneous locomotor activity of animals 
and it’s not induced catalepsy. The catalepsy test has been used to predict tranquillizer activity 
as well as to evaluate motor effects of drugs, particularly those related to the extra-pyramidal 
system (Sanberg, et al., 1988). 
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In the present study, we did not observe any mortality case up to the doses of 1600 
mg/kg of the alkaloid fraction from Nauclea latifolia. Therefore, we may suggest that the 
extract has no lethal toxicity in mice. As seen, using the more sensitive MTT assay, no 
cytoxicity has been observed on CHO cells lines incubated with alkaloids fraction from 
Nauclea latifolia at 160 μg/ml. MTT assay measured the metabolism of 3- (4,5-
dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide to form formazan precipitate by 
mitochondrial dehydrogenase which only present in viable cells. Formazan accumulation 
directly reflected mitochondrial activity, which was an indirect measure of cell viability 
(Mosmann, 1983). 
In summary, a novel antinociceptive action of the alkaloid fraction from Nauclea 
latifolia has been confirmed against neuropathic pain induced by CCI of the sciatic nerve, a 
rat model of neuropathic pain, using the Von Frey and acetone tests, and showing no increase 
in side effects on motor coordination. Moreover, the anti-hyperalgesic and anti-allodynic 
action demonstrated in the present study supports, at least in part, the ethnomedical uses of 
this plant. 
 
Acknowledgements 
This research was supported by Grant from the Agence Universitaire de la 
Francophonie (Bourse Internationale de Formation à la Recherche Doctorale, AUF 
2009/2010, Ref.: 1021FR/277/BAC 2009/JGZ/AS) for valuable financial assistance. 
 
References 
Abbah, J., Amos, S., Ngazal, I., Vongtau, H., Adzu, B., Chindo, B., Farida, T., Odutola, A.A., 
Wammbebe, C., Gamaniel, K.S., 2009. Pharmacological evidence favouring the use of 
19 
 
Nauclea latifolia in malaria ethnopharmacy: Effect against nociception, inflammation, 
and pyrexia in rats and mice. Journal of Ethnopharmacology 127, 85-90. 
Adjanohoun, J.E., Aboukakar, N., Dramane, K., Ebot, M.E., Ekpere, J.A., Enow-Orock, E.G., 
Focho, D., Gbile, Z.O., Kamanyi, A., Kamsu, K.J., Keita, A., Mbenkum, T., Mbi, 
C.N., Mbiele, A.L., Mbome, I.L., Mubiru, N.K., Nancy, W.L., Nkongmeneck, B., 
Satabu, B., Sofowora, A., Tamze, V., Wirmum, C.K., 1996. Traditional medicine and 
pharmacopoeia. In: Contribution to Ethnobotanical and Floristic Studies in Cameroon. 
Centre de Production de Manuels Scolaires, Porto-Novo (Rep. Du Benin), p. 133. 
Amos, S., Abbah, J., Chindo, B., Edmond, I., Binda, L., Adzu, B., Buhari, S., Odutola, A.A., 
Wambebe, C., Gamaniel, K., 2005. Neuropharmacological effects of the aqueous 
extract of Nauclea latifolia root bark in rats and mice. Journal of Ethnopharmacology 
97, 53-57. 
Andersen, G., Vestergaard, K., Ingeman-Nielsen, M., Jensen, T.S., 1995. Incidence of central 
post-stroke pain. Pain 61, 187-193. 
Arbonnier, M., 2000. Arbres, arbustes et lianes des zones sèches d’Afrique de l’Ouest Trees, 
shrubs and lianas of West Africa dry zones, Mali, Ouagadougou: Centre de 
Coopération Internationale en Recherche Agronomique pour le 
développement/Muséum national d’histoire naturelle/Union mondiale pour la nature. 
1st Edn., (CIRAD/MNHN/UICN). 
Ata, A., Udenigwe, C.C., Matochko, W., Holloway, P., Eze, M.O., Uzoegwu, P.N., 2009. 
Chemical constituents of Nauclea latifolia and their anti-GST and anti-fungal 
activities. Natural Product Communications 4, 1185-1188.  
Bennett, G., Xie, Y.K., 1988. A peripheral mononeuropathy in rat that produces disorders of 
pain sensation like those seen in man. Pain 33, 87-107. 
Bennett, M., 2007. Neuropathic pain. Oxford University Press, Oxford, England. 
20 
 
Biholong, M., 1986. Contribution à l’étude de la flore du Cameroun: les Astéracées. Thèse de 
doctorat. Université de Bordeaux III, Bordeaux, France, pp 10 – 50.  
Choi, Y., Yoon, Y.W., Na, H.S., Kim, S.H., Chung, J.M., 1994. Behavioral signs of ongoing 
pain and cold alodynia in a rat model of neuropathic pain. Pain 59, 369-376. 
Dalziel, J.M., 1937. The useful plants of West Tropical Africa. Ed. The Crown Agency for the 
Colonies, London. 
Davies, M., Brophy. S., Williams, R., Taylor, A., 2006. The prevalence, severity, and impact 
of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 29, 1518-
1522. 
De Vry, J., Kuhl, E., Franken-Kunkel, P., Eckel, G., 2004. Pharmacological characterization 
of the chronic constriction injury model of neuropathic pain. European Journal 
Pharmacology  491, 137-148. 
De la O-Arciniega, M., Díaz-Reval, M.I., Cortés-Arroyo, A.R., Domínguez-Ramírez, A.M., 
López-Muñoz, F.J., 2009. Anti-nociceptive synergism of morphine and gabapentin in 
neuropathic pain induced by chronic constriction injury. Pharmacology, Biochemistry 
and Behavior 92, 457-464. 
Dowdall, T., Robinson, I., Meert, F.T., 2005. Comparison of five different rat models of 
peripheral nerve injury. Pharmacology Biochemistry and Behavior 80, 93-108. 
Hewitt, D.J, McDonald, M., Portenoy, R.K., Rosenfeld, B., Passik, S., Breitbart, W., 1997. 
Pain syndromes and etiologies in ambulatory AIDS patients. Pain 70, 117-123. 
Jung, B.F., Johnson, R.W., Griffin, D.R., Dworkin, R.H., 2004. Risk factors for postherpetic 
neuralgia in patients with herpes zoster. Neurology  62,1545-1555. 
Kehlet, H., Jensen, T.S., Woolf, C.J., 2006. Persistent postsurgical pain: risk factors and 
prevention. Lancet 367, 1618-25. 
21 
 
Kim, S.H., Chung, J.M., 1992. An experimental model for peripheral neuropathy produced by 
segmental spinal nerve ligation in the rat. Pain 50, 355-63. 
Litchfield, J.T., Wilcoxon, F., 1949. A simplified method of evaluating dose-effect 
experiments. Journal of Pharmacology and Experimental Therapeutics 96, 99-113. 
López-Muñoz, F.J., Salazar, L.A., Castañeda-Hernández, G., Villarreal, J.E., 1993. A new 
model to assess analgesic activity: pain-induced functional impairment in the rat 
(PIFIR). Drug Development Research 28, 169-75. 
Merskey, H., 1991. The definition of pain. European Journal of Psychiatry 6, 153-9. 
Moalem, G., Tracey, D.J., 2006. Immune and inflammatory mechanisms in neuropathic pain. 
Brain Research Reviews 51, 240-64. 
Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to 
proliferation and cytotoxicity assays. Journal of Immunological Methods 65, 55-63. 
Ngo Bum, E., Taïwe, G.S., Moto, F.C.O., Ngoupaye, G.T., Nkantchoua, G.N., Pelanken, 
M.M., Rakotonirina, S.V., Rakotonirina, A., 2009. Anticonvulsant, anxiolytic and 
sedative properties of the roots of Nauclea latifolia Smith in mice. Epilepsy and 
Behavior 15, 434-440. 
Nicholson, B., 2003. Responsible prescribing of opioids for the management of chronic pain. 
Drugs, 63: 17-32. 
Osterberg, A., Boivie, J., Thuomas, K.A., 2005. Central pain in multiple sclerosis–prevalence 
and clinical characteristics. European Journal of Pain 9, 531-42. 
Poillot, C., Dridi, K., Bichraoui, H., Pêcher, J., Alphonse, S., Douzi, B., Ronjat, M., Darbon, 
H., and De Waard, M., 2010. D-maurocalcine, a pharmacologically-inert efficient cell 
penetrating peptide analogue. The Journal of Biological Chemistry 285, 34168-34180. 
Rowland, M., Tozer, N.T., 1989. Clinical pharmacokinetics: concepts and applications. 
Chapter 19. Lea and Febiger, 2nd edition London.  
22 
 
Sanberg, P.R., Bunsey, M.D., Giordano, M., Norman, A.B., 1988. The catalepsy test: its ups 
and downs. Behavioural Neuroscience 102, 748-759. 
Shigemori, H., Kagata, T., Ishiyama, H., Morah, F., Ohsaki, A., Kobayash, J., 2002. 
Nucleamides A-E, new monotherpene indole alkaloids from Nauclea latifolia. 
Chemical and Pharmaceutical Bulletin, 51, 58-61. 
Siddall, P.J., Mc-Clelland, J.M., Rutkowski, S.B., Cousins, M.J., 2003. A longitudinal study 
of the prevalence and characteristics of pain in the first 5 years following spinal cord 
injury. Pain, 103: 249-57. 
Sindrup, S.H., Jensen, T.S., 2000. Pharmacologic treatment of pain in polyneuropathy. 
Neurology 55, 915-20. 
Taïwe, G.S., Ngo Bum, E., Dimo, T., Talla, E., Weiss, N., Amadou, D., Moto O.F.C., Sidiki, 
N., Dzeufiet P.D., De Waard M., 2010. Antidepressant, myorelaxant and anti-anxiety-
like effects of Nauclea latifolia Smith (Rubiaceae) roots extract in murine models. 
International Journal of Pharmacology 6, 326-333. 
Taïwe, G.S., Ngo Bum, E., Dimo, T., Talla, E., Weiss, N., Sidiki, N., Amadou, D., Moto, 
O.F.C., Dzeufiet, P.D., De Waard, M., 2011. Antipyretic and antinociceptive effects of 
Nauclea latifolia and possible mechanisms of action. Pharmaceutical Biology 49, 15-
25. 
Ueda, H., Rashid, H., 2003. Molecular mechanism of neuropathic pain. Drug News and 
Perspectives 16, 605-13. 
Werhagen, L., Hultling, C., Molander, C., 2007. The prevalence of neuropathic pain after non 
traumatic spinal cord lesion. Spinal Cord 45, 609-615. 
 
Figure legends 
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Figure 1: HPLC profile of the alkaloid fraction from the roots of Nauclea latifolia alone 
measured at the wavelength of 215 nm. 
 
Figure 2: Effects of the alkaloid fraction from Nauclea latifolia on mechanical hyperalgesia. 
Time course of anti-hyperalgesic effects of Nauclea latifolia on mechanical hyperalgesia with 
a 15 g von Frey filament after CCI of the sciatic nerve (A). Control groups (sham and CCI) 
were treated with equivalent volumes of vehicle. Data are expressed as mean ± SEM, n = 6, 
aP<0.05, bP<0.01 and cP<0.001 versus vehicle (CCI). Dose-response curves expressed as the 
area under curve (AUC) for the antihyperalgesic effects of Nauclea latifolia with a von Frey 
filament (15 g) after CCI of the sciatic nerve in rats (B). Rats were treated with vehicle or 
morphine (Morp; 5.6 mg/kg, s.c.). Bars are means ± SEM, n = 6. *P<0.05, **P<0.01 and 
***P<0.001 versus vehicle (CCI). Data were analyzed by a two-way analysis of variance 
(ANOVA) followed by Bonferroni’s post-hoc tests. 
 
Figure 3: Effects of the alkaloid fraction from Nauclea latifolia on cold allodinia. Time 
course of anti-allodynic effects of Nauclea latifolia on cold allodynia after CCI of the sciatic 
nerve (A). Control groups (sham and CCI) were treated with equivalent volumes of vehicle. 
Data are expressed as mean ± SEM, n=6, aP<0.05, bP<0.01 and cP<0.001 versus vehicle 
(CCI). Area under the curve (AUC) of anti-allodynic effects produced by Nauclea latifolia on 
cold allodynia after CCI of the sciatic nerve (B). Rats were treated with vehicle or morphine 
(Morp; 5.6 mg/kg, s.c.). Bars are means ± SEM, n = 6. *P<0.05, **P<0.01 and ***P<0.001 
versus vehicle (CCI). Data were analyzed by a two-way analysis of variance (ANOVA) 
followed by Bonferroni’s post-hoc tests. 
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Figure 4: Effects of the alkaloid fraction from Nauclea latifolia (8, 16, 40 and 80 mg/kg) on 
catalepsy in mice. Morphine (Morp; 5.6 mg/kg) was used as a positive control. Bars are 
means ± SEM, n = 8. **p < 0.01 and ***P<0.001 compared to vehicle by using a two-way 
analysis of variance (ANOVA) followed by Bonferroni’s post-hoc tests. 
 
Figure 5: Dose response curves for CHO cell line following 24 hours continuous exposure to 
the alkaloid fraction from Nauclea latifolia. Results are the mean of three determinations and 
are expressed as % cell survival. EC50 = 772.35 ± 13.41 µg/kg. 
 
Tables 
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Table 1: Effects of the alkaloid fraction from Nauclea latifolia on motor coordination of mice on the rotarod apparatus. 
Treatments Dose (mg/kg) Duration of study (min) 
t0b t0a 30 60 90 120 
Vehicle − 0.77 ± 0.11 1.11 ± 0.39 1.55 ± 0.83 1.88 ± 1.02 1.55 ± 0.48 1.44 ± 0.49 
N. latifolia 8 0.88 ± 0.14 1.33 ± 0.44 1.22 ± 0.52 1.77 ± 1.31 1.88 ± 0.39 1.55 ± 0.61 
N. latifolia 16 0.77 ± 0.44 1.22 ± 0.34 1.11 ± 0.39 2.16 ± 1.01 1.66 ± 0.58 1.66 ± 0.74 
N. latifolia 40 0.55 ± 0.44 1.44 ± 0.59 1.33 ± 0.81 1.11 ± 0.61 1.88± 0.59 0.88 ± 0.19 
N. latifolia 80 0.77 ± 0.44 1.33 ± 0.81 1.22 ± 0.69 1.66 ± 0.61 2.11 ± 0.39 1.11 ± 0.19 
Morphine 5.6 0.66 ± 0.44 0.88 ± 0.39 16.55 ± 1.72*** 19.22 ± 0.91*** 19.44 ± 0.83*** 18.77 ± 0.74 *** 
Acquisition process of the rotarod performance as expressed by means ± S.E.M. of number of falls, n = 6 animals per group, ***p< 0.001, 
significantly different compared to the control. Data were analysed by two-way analysis of variance (ANOVA) followed by Bonferroni’s post-
hoc tests.  
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Figure 1: Germain Sotoing Taïwe et al. 
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Figure 2: Germain Sotoing Taïwe et al. 
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Figure 3: Germain Sotoing Taïwe et al. 
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Figure 4: Germain Sotoing Taïwe et al. 
 
 
 
 
 
 
 
 
 
 
 
30 
 
 
 
Figure 5: Germain Sotoing Taïwe et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
